Email Updates

You are here


PrEP works. Investment in more options must continue, and faster, smarter rollout must be a top priority.

Clinical trials have shown that different types of pre-exposure prophylaxis (PrEP) using antiretroviral (ARVs) drugs dramatically reduce the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal. Meanwhile the landscape is changing as more options move through research and development, creating important opportunities and intensifying the need to improve implementation.

TDF/FTC is approved for use as oral PrEP in dozens of countries, but PrEP still has not reached many of the people who need it most. Since TDF/FTC (brand name Truvada) was approved in 2012, two other interventions, F/TAF and cabotegravir, have been found to be safe and effective among some populations.

Among all these interventions and other ARVs still in the R & D pipeline, advocacy is crucial on a number of fronts. There must be continued investment in the development of additional options, community engagement must be integrated from trial design to implementation, and improved programming must support those who need HIV prevention options the most.

Key Update

AVAC’s statement on the news that cabotegravir has demonstrated initial safety and efficacy in cisgender men who have sex with men and transgender women. Read on to learn about AVAC’s call for the trial of cabotegravir among cisgender women to continue with urgency and to accelerate planning for possible introduction of this new option to prevent HIV.

May 18, 2020
What We're Reading

A long-acting antiretroviral drug given as an injection every two months powerfully protected uninfected people from HIV in a large-scale study that was disrupted by the COVID-19 pandemic.

May 18, 2020

This study provides valuable insights on early rollout of PrEP of how clients perceive oral PrEP and where to target efforts to improve the uptake of this highly effective HIV prevention product. By identifying strengths and areas for improvement, the ACCESS study has generated evidence that can be used to guide high quality scale-up in South Africa and may be instructive for other countries’ efforts to expand quality access to oral PrEP.

April 30, 2020

In states where pre-exposure prophylaxis (PrEP) use has become more popular, HIV diagnoses have been declining in recent years, Infectious Disease Advisor reports.

April 28, 2020
Subscribe to RSS - PrEP